To confirm that KRASG12V- or BRAFV600E-dependent expression of EmGFP was dependent on signalling through the RAS–RAF–MEK–ERK1/2 pathway we used the potent and selective ERK1/2 inhibitor, SCH772984, and the potent, allosteric MEK1/2 inhibitor, Trametinib, which is clinically approved for the treatment of melanoma. Here, MAP2K7 is linked to melanoma.